Abstract
The phosphate group present in the ATP (adenosine triphosphate) is transferred to the hydroxy group-containing tyrosine, serine, or threonine residue by the protein kinases encoded in the human genome. Till now, a large number of these kinases have been reported to be associated with the initiation and progression of human cancers. In clinical trials, it has been demonstrated that small-molecule kinase inhibitors can effectively cure a wide range of cancers. The FDA approved more than 40 kinase inhibitors for cancer treatment since the early 1980s when the first protein kinase inhibitor was developed. In this review, the authors explained the relevancies of the kinase with cancer. In addition, several FDA-approved drug candidates have been classified according to their binding with kinases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
